These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
547 related articles for article (PubMed ID: 34539622)
1. A Transcriptional Signature of PDGF-DD Activated Natural Killer Cells Predicts More Favorable Prognosis in Low-Grade Glioma. Sun Y; Sedgwick AJ; Palarasah Y; Mangiola S; Barrow AD Front Immunol; 2021; 12():668391. PubMed ID: 34539622 [TBL] [Abstract][Full Text] [Related]
2. A Transcriptional Signature of IL-2 Expanded Natural Killer Cells Predicts More Favorable Prognosis in Bladder Cancer. Sun Y; Sedgwick AJ; Khan MA; Palarasah Y; Mangiola S; Barrow AD Front Immunol; 2021; 12():724107. PubMed ID: 34858395 [TBL] [Abstract][Full Text] [Related]
3. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data. Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666 [TBL] [Abstract][Full Text] [Related]
4. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma. Hao YP; Wang WY; Qiao Q; Li G Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884 [TBL] [Abstract][Full Text] [Related]
5. Natural Killer Cells Control Tumor Growth by Sensing a Growth Factor. Barrow AD; Edeling MA; Trifonov V; Luo J; Goyal P; Bohl B; Bando JK; Kim AH; Walker J; Andahazy M; Bugatti M; Melocchi L; Vermi W; Fremont DH; Cox S; Cella M; Schmedt C; Colonna M Cell; 2018 Jan; 172(3):534-548.e19. PubMed ID: 29275861 [TBL] [Abstract][Full Text] [Related]
6. SCAMP4 is a novel prognostic marker and correlated with the tumor progression and immune infiltration in glioma. Ge X; Wang Z; Jiang R; Ren S; Wang W; Wu B; Zhang Y; Liu Q Int J Biochem Cell Biol; 2021 Oct; 139():106054. PubMed ID: 34390854 [TBL] [Abstract][Full Text] [Related]
7. Aberrant expression of RSK1 characterizes high-grade gliomas with immune infiltration. M Hajj GN; da Silva FF; de Bellis B; Lupinacci FCS; Bellato HM; Cruz JR; Segundo CNC; Faquini IV; Torres LC; Sanematsu PI; Begnami MD; Martins VR; Roffé M Mol Oncol; 2020 Jan; 14(1):159-179. PubMed ID: 31701625 [TBL] [Abstract][Full Text] [Related]
8. TGF-β Score based on Zhang W; Yan Z; Zhao F; He Q; Xu H Recent Pat Anticancer Drug Discov; 2024; 19(5):610-621. PubMed ID: 37718518 [TBL] [Abstract][Full Text] [Related]
9. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma. Xu S; Tang L; Liu Z; Luo C; Cheng Q Front Immunol; 2021; 12():731048. PubMed ID: 34659218 [TBL] [Abstract][Full Text] [Related]
10. A gene expression-based study on immune cell subtypes and glioma prognosis. Zhong QY; Fan EX; Feng GY; Chen QY; Gou XX; Yue GJ; Zhang GH BMC Cancer; 2019 Nov; 19(1):1116. PubMed ID: 31729963 [TBL] [Abstract][Full Text] [Related]
11. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas. Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L Front Immunol; 2020; 11():603341. PubMed ID: 33363544 [TBL] [Abstract][Full Text] [Related]
12. Characterization of the Clinical Significance of PD-1/PD-Ls Expression and Methylation in Patients With Low-Grade Glioma. Mei J; Cai Y; Xu R; Yang X; Zhou W; Wang H; Liu C Technol Cancer Res Treat; 2021; 20():15330338211011970. PubMed ID: 33955303 [TBL] [Abstract][Full Text] [Related]
13. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma. Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355 [TBL] [Abstract][Full Text] [Related]
14. Identification and validation of a risk signature based on extracellular matrix-related genes in gliomas. Liu J; Li G Medicine (Baltimore); 2021 Apr; 100(16):e25603. PubMed ID: 33879726 [TBL] [Abstract][Full Text] [Related]
15. Prognostic Gene Expression Signature in Patients With Distinct Glioma Grades. Ait Ssi S; Chraa D; El Azhary K; Sahraoui S; Olive D; Badou A Front Immunol; 2021; 12():685213. PubMed ID: 34539626 [TBL] [Abstract][Full Text] [Related]
16. Classification of diffuse lower-grade glioma based on immunological profiling. Wu F; Wang ZL; Wang KY; Li GZ; Chai RC; Liu YQ; Jiang HY; Zhai Y; Feng YM; Zhao Z; Zhang W Mol Oncol; 2020 Sep; 14(9):2081-2095. PubMed ID: 32392361 [TBL] [Abstract][Full Text] [Related]
17. Six Immune Associated Genes Construct Prognostic Model Evaluate Low-Grade Glioma. Tan YQ; Li YT; Yan TF; Xu Y; Liu BH; Yang JA; Yang X; Chen QX; Zhang HB Front Immunol; 2020; 11():606164. PubMed ID: 33408717 [TBL] [Abstract][Full Text] [Related]
18. PDGF-D-PDGFRβ signaling enhances IL-15-mediated human natural killer cell survival. Ma S; Tang T; Wu X; Mansour AG; Lu T; Zhang J; Wang LS; Caligiuri MA; Yu J Proc Natl Acad Sci U S A; 2022 Jan; 119(3):. PubMed ID: 35027451 [TBL] [Abstract][Full Text] [Related]
19. Profiles of immune-related genes and immune cell infiltration in the tumor microenvironment of diffuse lower-grade gliomas. Deng X; Lin D; Zhang X; Shen X; Yang Z; Yang L; Lu X; Yu L; Zhang N; Lin J J Cell Physiol; 2020 Oct; 235(10):7321-7331. PubMed ID: 32162312 [TBL] [Abstract][Full Text] [Related]
20. A Novel 10-Gene Signature Predicts Poor Prognosis in Low Grade Glioma. Liu W; Zou J; Ren R; Liu J; Zhang G; Wang M Technol Cancer Res Treat; 2021; 20():1533033821992084. PubMed ID: 33550903 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]